These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 8354737)

  • 1. A predictive study of obsessive-compulsive disorder response to clomipramine.
    Alarcon RD; Libb JW; Spitler D
    J Clin Psychopharmacol; 1993 Jun; 13(3):210-3. PubMed ID: 8354737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of drug treatment response in obsessive-compulsive disorder.
    Ravizza L; Barzega G; Bellino S; Bogetto F; Maina G
    J Clin Psychiatry; 1995 Aug; 56(8):368-73. PubMed ID: 7635854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of treatment response in obsessive-compulsive disorder: multivariate analyses from a multicenter trial of clomipramine.
    Ackerman DL; Greenland S; Bystritsky A; Morgenstern H; Katz RJ
    J Clin Psychopharmacol; 1994 Aug; 14(4):247-54. PubMed ID: 7962680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder--a multicenter trial.
    DeVeaugh-Geiss J; Moroz G; Biederman J; Cantwell D; Fontaine R; Greist JH; Reichler R; Katz R; Landau P
    J Am Acad Child Adolesc Psychiatry; 1992 Jan; 31(1):45-9. PubMed ID: 1537780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
    Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ
    J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical predictors of treatment response in obsessive compulsive disorder: exploratory analyses from multicenter trials of clomipramine.
    DeVeaugh-Geiss J; Katz R; Landau P; Goodman W; Rasmussen S
    Psychopharmacol Bull; 1990; 26(1):54-9. PubMed ID: 2196627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clomipramine dosage reduction study in the course of long-term treatment of obsessive-compulsive disorder patients.
    Pato MT; Hill JL; Murphy DL
    Psychopharmacol Bull; 1990; 26(2):211-4. PubMed ID: 2236458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features associated with treatment response in obsessive-compulsive disorder.
    Shavitt RG; Belotto C; Curi M; Hounie AG; Rosário-Campos MC; Diniz JB; Ferrão YA; Pato MT; Miguel EC
    Compr Psychiatry; 2006; 47(4):276-81. PubMed ID: 16769302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptoms and physiologic manifestations in obsessive compulsive patients before and after treatment with clomipramine.
    Hoehn-Saric R; McLeod DR; Zimmerli WD; Hipsley PA
    J Clin Psychiatry; 1993 Jul; 54(7):272-6. PubMed ID: 8335655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Progress and therapeutic response in the obsessive-compulsive disorder].
    Chinchilla Moreno A; Padín Calo JJ; Vega Piñero M; Llinares Zaragoza C; Fabregat Navarro V; Díaz Marsa M
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1995; 23(1):9-19. PubMed ID: 7717153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels.
    Mavissakalian MR; Jones B; Olson S; Perel JM
    J Clin Psychopharmacol; 1990 Aug; 10(4):261-8. PubMed ID: 2286699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Family accommodation in obsessive-compulsive disorder: Relation to symptom dimensions, clinical and family characteristics.
    Albert U; Bogetto F; Maina G; Saracco P; Brunatto C; Mataix-Cols D
    Psychiatry Res; 2010 Sep; 179(2):204-11. PubMed ID: 20483467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature].
    Etain B; Bonnet-Perrin E
    Encephale; 2001; 27(3):280-9. PubMed ID: 11488259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.
    Sevincok L; Topuz A
    J Clin Psychopharmacol; 2003 Oct; 23(5):448-50. PubMed ID: 14520120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor analysis of the Yale-Brown Obsessive Compulsive Scale in a family study of obsessive-compulsive disorder.
    Cullen B; Brown CH; Riddle MA; Grados M; Bienvenu OJ; Hoehn-Saric R; Shugart YY; Liang KY; Samuels J; Nestadt G
    Depress Anxiety; 2007; 24(2):130-8. PubMed ID: 16892417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clomipramine: plasma levels, side effects and outcome in obsessive-compulsive neurosis.
    Stern RS; Marks IM; Wright J; Luscombe DK
    Postgrad Med J; 1980; 56 Suppl 1():134-9. PubMed ID: 7393824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prospective follow-up over a 12 month period of a cohort of 155 patients with obsessive-compulsive disorder: phase III National DRT-TOC Study].
    Hantouche EG; Bouhassira M; Lancrenon S
    Encephale; 2000; 26(6):73-83. PubMed ID: 11217541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symptom dimensions in obsessive-compulsive disorder: prediction of cognitive-behavior therapy outcome.
    Rufer M; Fricke S; Moritz S; Kloss M; Hand I
    Acta Psychiatr Scand; 2006 May; 113(5):440-6. PubMed ID: 16603035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship of plasma clomipramine and N-desmethylclomipramine to response in obsessive-compulsive disorder.
    Mavissakalian M; Jones B; Olson S; Perel JM
    Psychopharmacol Bull; 1990; 26(1):119-22. PubMed ID: 2371366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of obsessive-compulsive neurosis with clomipramine (Anafranil).
    Ananth J
    J Int Med Res; 1977; 5 Suppl 5():38-41. PubMed ID: 598604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.